Protagonist Therapeutics Working Capital Growth & History (PTGX)

Protagonist Therapeutics's working capital was $532.1M for fiscal 2025.

View full Protagonist Therapeutics company overview

Protagonist Therapeutics annual working capital history

Protagonist Therapeutics annual working capital

Fiscal yearPeriod endedWorking capitalChangeGrowth
20252025-12-31$532.1M−$12.1M−2.23%
20242024-12-31$544.2M$209.9M+62.80%
20232023-12-31$334.3M$122.4M+57.77%
20222022-12-31$211.9M−$84.8M−28.59%
20212021-12-31$296.7M$21.4M+7.76%
20202020-12-31$275.4M$165.5M+150.55%
20192019-12-31$109.9M−$1.4M−1.29%
20182018-12-31$111.3M$3.0M+2.72%
20172017-12-31$108.4M$31.6M+41.12%
20162016-12-31$76.8M$65.7M+593.22%
20152015-12-31$11.1M

Protagonist Therapeutics working capital trends

Over the last five fiscal years, Protagonist Therapeutics's working capital increased from $275.4M to $532.1M, a change of $256.8M. The latest reported quarter, Q2 2026, shows $770.0M.

About the metric

What working capital means

Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.

Calculation and source

How working capital is calculated

TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Protagonist Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about PTGX yet. Start the conversation.

Write the first post